PKCζ and PKMζ are overexpressed in TCF3-rearranged paediatric acute lymphoblastic leukaemia and are associated with increased thiopurine sensitivity

Leukemia

Volumn 29, Issue 2, 2015, Pages 304-311

  Hartsink Segers, S A ^a   Beaudoin, J J ^a   Luijendijk, M W J ^a   Exalto, C ^a   Pieters, R ^a,b   Den Boer, M L ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b Department of Radiation Oncology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; MESSENGER RNA; PROTEIN KINASE C ZETA; PROTEIN KINASE M ZETA; PROTEIN MSH2; PROTEIN SERINE THREONINE KINASE; TIOGUANINE; TRANSCRIPTION FACTOR 7 LIKE 1; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ISOENZYME; PROTEIN KINASE C; TCF3 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ARTICLE; B-CELL LEUKEMIA CELL LINE; BONE MARROW CELL; CELL PROLIFERATION; CELL SURVIVAL; CHILDHOOD LEUKEMIA; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEQUENCE ALIGNMENT; BLOOD; CHEMISTRY; CYTOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; LENTIVIRINAE; METABOLISM; MONONUCLEAR CELL; PHOSPHORYLATION; TUMOR CELL LINE;

6-MERCAPTOPURINE; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HEK293 CELLS; HUMANS; ISOENZYMES; LENTIVIRUS; LEUKOCYTES, MONONUCLEAR; PHOSPHORYLATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE C; THIOGUANINE;

EID: 84922521974     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.210     Document Type: Article

References (38)

1. Hirai T, Chida K. Protein Kinase Cζ (PKCζ): activation mechanisms and cellular functions. J Biochem 2003; 133 : 1-7.
2. Diaz-Meco MT, Berra E, Municio MM, Sanz L, Lozano J, Dominguez I et al. A dominant negative protein kinase C zeta subspecies blocks NF-kappa B activation. Mol Cell Biol 1993; 13: 4770-4775.
3. Dominguez I, Sanz L, Arenzana-Seisdedos F, Diaz-Meco MT, Virelizier JL, Moscat J. Inhibition of protein kinase C zeta subspecies blocks the activation of an NF-kappa B-like activity in Xenopus laevis oocytes. Mol Cell Biol 1993; 13: 1290-1295.
4. Berra E, Diaz-Meco MT, Lozano J, Frutos S, Municio MM, Sanchez P et al. Evidence for a role of MEK and MAPK during signal transduction by protein kinase C zeta. EMBO J 1995; 14: 6157-6163.
5. Leitges M, Sanz L, Martin P, Duran A, Braun U, García JF et al. Targeted disruption of the ζPKC gene results in the impairment of the NF-κB pathway. Mol Cell 2001; 8: 771-780.
6. Hernandez-Pigeon H, Quillet-Mary A, Louat T, Schambourg A, Humbert O, Selves J et al. hMutS alpha is protected from ubiquitin-proteasome-dependent degradation by atypical protein kinase C zeta phosphorylation. J Mol Biol 2005; 348: 63-74.
7. Ways D, Posekany K, deVente J, Garris T, Chen J, Hooker J et al. Overexpression of protein kinase C-zeta stimulates leukemic cell differentiation. Cell Growth Differ 1994; 5: 1195-1203.
8. Guo H, Ma Y, Zhang B, Sun B, Niu R, Ying G et al. Pivotal advance: PKCζ is required for migration of macrophages. J Leukocyte Biol 2009; 85: 911-918.
9. Li H, Wu J, Ying G, Chen L, Lai L, Liu Z et al. J-4: a novel and typical preclinical anticancer drug targeting protein kinase C zeta. Anticancer Drugs 2012; 23: 691-697.
10. Nazarenko I, Jenny M, Keil J, Gieseler C, Weisshaupt K, Sehouli J et al. Atypical protein kinase C ζ exhibits a proapoptotic function in ovarian cancer. Mol Cancer Res 2010; 8: 919-934.
11. Galvez AS, Duran A, Linares JF, Pathrose P, Castilla EA, Abu-Baker S et al. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo . Mol Cell Biol 2009; 29: 104-115.
12. Luna-Ulloa LB, Hernández-Maqueda JG, Santoyo-Ramos P, Castañeda-Patlán MC, Robles-Flores M. Protein kinase C ζ is a positive modulator of canonical Wnt signaling pathway in tumoral colon cell lines. Carcinogenesis 2011; 32: 1615-1624.
13. Diouf B, Cheng Q, Krynetskaia NF, Yang W, Cheok M, Pei D et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 2011; 17: 1298-1303.
14. Takai Y, Kishimoto A, Inoue M, Nishizuka Y. Studies on a cyclic nucleotideindependent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. J Biol Chem 1977; 252: 7603-7609.
15. Sacktor TC, Osten P, Valsamis H, Jiang X, Naik MU, Sublette E. Persistent activation of the zeta isoform of protein kinase C in the maintenance of long-term potentiation. Proc Natl Acad Sci USA 1993; 90: 8342-8346.
16. Bougie JK, Lim T, Farah CA, Manjunath V, Nagakura I, Ferraro GB et al. The atypical protein kinase C in Aplysia can form a protein kinase M by cleavage. J Neurochem 2009; 109: 1129-1143.
17. Osten P, Valsamis L, Harris A, Sacktor TC. Protein synthesis-dependent formation of protein kinase Mzeta in long-term potentiation. J Neurosci 1996; 16: 2444-2451.
18. Marshall BS, Price G, Powell CT. Rat protein kinase c zeta gene contains alternative promoters for generation of dual transcripts with 5'-end heterogeneity. DNA Cell Biol 2000; 19: 707-719.
19. Hernandez AI, Blace N, Crary JF, Serrano PA, Leitges M, Libien JM et al. Protein kinase M zeta synthesis from a brain mRNA encoding an independent protein kinase C zeta catalytic domain. Implications for the molecular mechanism of memory. J Biol Chem 2003; 278: 40305-40316.
20. Kelly MT, Crary JF, Sacktor TC. Regulation of protein kinase Mzeta synthesis by multiple kinases in long-term potentiation. J Neurosci 2007; 27: 3439-3444.
21. Sacktor TC The Research Foundation of State University of NY, assignee. Memory Enhancing Protein. US patent 7928070, 19 April 2011.
22. Naik MU, Benedikz E, Hernandez I, Libien J, Hrabe J, Valsamis M et al. Distribution of protein kinase Mzeta and the complete protein kinase C isoform family in rat brain. J Comp Neurol 2000; 426: 243-258.
23. Ling DSF, Benardo LS, Serrano PA, Blace N, Kelly MT, Crary JF et al. Protein kinase M [zeta] is necessary and sufficient for LTP maintenance. Nat Neurosci 2002; 5: 295-296.
24. Drier EA, Tello MK, Cowan M, Wu P, Blace N, Sacktor TC et al. Memory enhancement and formation by atypical PKM activity in Drosophila melanogaster. Nat Neurosci 2002; 5: 316-324.
25. Pui C-H, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012; 120: 1165-1174.
26. Lopez-Garcia Laura A, Schulze Jörg O, Fröhner W, Zhang H, Süß E, Weber N et al. Allosteric regulation of protein kinase PKC ζ by the N-terminal C1 domain and small compounds to the PIF-pocket. Chem Biol 2011; 18: 1463-1473.
27. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profi les in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262-3268.
28. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10: 125-134.
29. Hartsink-Segers SA, Exalto C, Allen M, Williamson D, Clifford SC, Horstmann M et al. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells. Haematologica 2013; 98: 1539-1546.
30. Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF et al. Aurora kinases in childhood acute leukemia: the promise of Aurora B as therapeutic target. Leukemia 2013; 27: 560-568.
31. Van Dijk MA, Voorhoeve PM, Murre C. Pbx1 is converted into a transcriptional activator upon acquiring the N-terminal region of E2A in pre-B-cell acute lymphoblastoid leukemia. Proc Natl Acad Sci USA 1993; 90: 6061-6065.
32. Lu Q, Wright DD, Kamps MP. Fusion with E2A converts the Pbx1 homeodomain protein into a constitutive transcriptional activator in human leukemias carrying the t(1;19) translocation. Mol Cell Biol 1994; 14: 3938-3948.
33. Diakos C, Xiao Y, Zheng S, Kager L, Dworzak M, Wiemels JL. Direct and indirect targets of the E2A-PBX1 leukemia-specific fusion protein. PLoS One 2014; 9: e87602.
34. Liu Y, Wang B, Wang J, Wan W, Sun R, Zhao Y et al. Down-regulation of PKCζ expression inhibits chemotaxis signal transduction in human lung cancer cells. Lung Cancer 2009; 63: 210-218.
35. Sun R, Gao P, Chen L, Ma D, Wang J, Oppenheim JJ et al. Protein kinase C ζ is required for epidermal growth factor -induced chemotaxis of human breast cancer cells. Cancer Res 2005; 65: 1433-1441.
36. Lee AW. The role of atypical protein kinase C in CSF-1-dependent Erk activation and proliferation in myeloid progenitors and macrophages. PLoS One 2011; 6: e25580.
37. Krynetskaia NF, Brenner TL, Krynetski EY, Du W, Panetta JC, Ching-Hon P et al. Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in Msh2-/- mice. Mol Pharmacol 2003; 64: 456-465.
38. Frost BM, Forestier E, Gustafsson G, Nygren P, Hellebostad M, Jonmundsson G et al. Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemia. Leukemia 2005; 19: 165-169.